The GABA(B)-receptor antagonist, CGP 35348, antagonises γ-hydroxybutyrate- and baclofen-induced alterations in locomotor activity and forebrain dopamine levels in mice

Journal of Neural Transmission

Volumn 103, Issue 11, 1996, Pages 1255-1263

  Nissbrandt, H ^a   Engberg, G ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Baclofen; CGP 35348; Dopamine; GABA(B) receptors; Locomotor activity; hydroxybutyric acid

Indexed keywords

3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 HYDROXYBUTYRIC ACID; BACLOFEN; DOPAMINE; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ORGANOPHOSPHORUS COMPOUND; OXYBATE SODIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; FOREBRAIN; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CHEMICAL PHENOMENA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MOTOR ACTIVITY;

ANIMALS; BACLOFEN; DEPRESSION, CHEMICAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GABA AGONISTS; GABA ANTAGONISTS; MALE; MICE; MOTOR ACTIVITY; ORGANOPHOSPHORUS COMPOUNDS; PROSENCEPHALON; RECEPTORS, GABA-B; SODIUM OXYBATE;

EID: 0029658028     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01271186     Document Type: Article

References (42)

1. Andén N-E, Wachtel H (1977) Biochemical effects of baclofen (β-parachlorophenyl-GABA) on the dopamine and the noradrenaline in the rat brain. Acta Pharmacol Toxicol 40: 310-320
2. Anton AH, Sayre DF (1962) A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines. J Pharmacol Exp Ther 138: 360-375
3. B) receptor mediated release of GABA and glutamate (Glu) in rat thalamic ventrobasal nucleus (VB): a possible mechanism for the generation of absence-like seizures induced by GHB. J Pharmacol Exp Ther 273: 1534-1543
4. Benavides J, Rumigny JF, Bourguignon JJ, Cash C, Wermuth C, Mandel P, Vincendon G, Maitre M (1982) High affinity binding sites for y-hydroxybutyric acid in rat brain. Life Sci 30: 953-961
5. Beninger RJ (1983) The role of dopamine in locomotor activity and learning. Brain Res Rev 6: 173-196
6. B receptors. J Neural Transm [Suppl] 35: 155-177
7. Bessman SP, Fishbein WN (1963) Gamma-hydroxybutyrate, a normal brain metabolite. Nature: 1207-1208
8. Biggio G, Cibin M, Diana M, Fadda F, Ferrara SD, Gallimberti L, Gessa GL, Mereu GP, Rossetti ZL, Serra M (1992) Suppression of voluntary alcohol intake in rats and alcoholics by gamma-hydroxybutyric acid: a non-GABAergic mechanism. In: Biggio G, Concas A, Costa E (eds) GABAergic synaptic transmission. Raven Press, New York, pp 281-288
9. Bloom FE, Schulman JA, Koob GF (1989) Catecholamines and behavior. In: Trendelenburg U, Weiner N (eds) Handbook of experimental pharmacology, vol 90/II. Catecholamines II. Springer, Berlin Heidelberg New York Tokyo, pp 27-88
10. B, receptor. J Pharmacol Exp Ther 265: 765-770
11. B receptor pharmacology. Ann Rev Pharmacol Toxicol 33: 109-147
12. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacol 1: 179-186
13. Colombo G, Agabio R, Lobina C, Reali R, Fadda F, Gessa GL (1995a) Cross-tolerance to ethanol and γ-hydroxybutyric acid. Eur J Pharmacol 273: 235-238
14. Colombo G, Agabio R, Balaklievskaia N, Diaz G, Lobina C, Reali R, Gessa GL (1995b) Oral self-administration of γ-hydroxybutyric acid in the rat. Eur J Pharmacol 285: 103-107
15. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM (1989) A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 12: 1-13
16. Diana M, Pistis M, Muntoni A, Gessa G (1991) Heterogenous responses of substantia nigra pars reticulata neurons to γ-hydroxybutyric acid administration. Eur J Pharmacol 230: 363-365
17. B-receptors. Naunyn Schmiedebergs Arch Pharmacol 348: 491-497
18. B-receptor activation alters the firing pattern of dopamine neurons in the rat substantia nigra. Synapse 15: 229-238
19. Felice LJ, Felice JD, Kissinger PT (1978) Determination of catecholamines in rat brain parts by reverse-phase ion-pair liquid chromatography. J Neurochem 31: 1461-1465
20. Food and Drug Administration (1991) Warning about GHBA. J Am Med Assoc 265: 1802
21. Gessa GL, Vargiu L, Crabai F, Boero GC, Caboni F, Camba R (1966) Selective increase of brain dopamine induced by gamma-hydroxybutyrate. Life Sci 5: 1921-1930
22. Gessa GL, Crabai F, Vargiu L, Spano PF (1968) Selective increase of brain dopamine induced by γ-hydroxybutyrate: study of the mechanism of action. J Neurochem 15: 377-381
23. Gianutsos G, Moore KE (1978) Tolerence to the effects of baclofen and γ-butyrolactone on locomotor activity and dopaminergic neurons in the mouse. J Pharmacol Exp Ther 207: 859-869
24. Imperato A, Di Chiara G (1984) Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites. J Neurosci 4: 966-977
25. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20: 379-382
26. Maitre M, Rumigny JF, Cash CD, Mandel P (1983) Subcellular distribution of γ-hydroxybutyrate binding sites in rat brain. Principal localization in the synaptosomal fraction. Biochem Biophys Res Commun 110: 262-265
27. B receptors and the effects of baclofen in the mammalian central nervous system. Prog Neurobiol 46: 423-462
28. B-receptors. Eur J Pharmacol 187: 27-38
29. Roth RH, Giarman NJ (1970) Natural occurrence of gamma-hydroxybutyric acid in mammalian brain. Biochem Pharmacol 21: 2111-2121
30. Roth RH, Walters JR, Aghajanian GK (1973) Effect of impulse flow on the release and synthesis of dopamine in the rat striatum. In: Snyder SH, Usdin E (eds) Frontiers in catecholamine research. Pergamon Press, New York, pp 567-574
31. Santiago M, Westerink BHC (1991) Characterization and pharmacological responsiveness of dopamine release recorded by microdialysis in the substantia nigra of conscious rats. J Neurochem 57: 738-747
32. A receptor complex in the rat cerebral cortex. Psychopharmacol 104: 351-355
33. Snead OC (1977) Minireview: gamma-hydroxybutyrate. Life Sci 20: 1935-1943
34. A receptor function in the γ-hydroxybutyrate model of generalized absence seizures. Neuropharmacol 32: 401-409
35. Stock G, Magnusson T, Andén N-E (1973) Increase in brain dopamine after axotomy or treatment with gammahydroxybutyric acid due to elimination of the nerve impulse flow. Naunyn Schmiedebergs Arch Pharmacol 278: 347-361
36. Tunnicliff G (1992) Significance of γ-hydroxybutyric acid in the brain. Gen Pharmacol 23: 1027-1034
37. Vayer P, Mandel P, Maitre M (1987) Gamma-hydroxybutyrate, a possible neurotransmitter. Life Sci 41: 1547-1557
38. Wachtel H, Andén, N-E (1978) Motor activity of rats following intracerebral injections of drugs influencing GABA mechanisms. Naunyn Schmiedebergs Arch Pharmacol 302: 133-139
39. B-antagonist, CGP 35348, antagonises the effects of baclofen, γ-butyrolactone and HA 966 on rat striatal dopamine synthesis. Naunyn Schmiedebergs Arch Pharmacol 343: 173-178
40. Walters JR, Roth RH (1972) Effect of gamma-hydroxybutyrate on dopamine and dopamine metabolites in the rat striatum. Biochem Pharmacol 21: 2111-2121
41. B receptors. Eur J Pharmacol 212: 291-294
42. Xie X, Smart TG (1992b) γ-Hydroxybutyrate depresses monosynaptic excitatory and inhibitory postsynaptic potentials in rat hippocampal slices. Eur J Pharmacol 223: 193-196